STAT3 and rheumatoid arthritis: LMT-28 could also suppress the differentiation of pro-inflammatory Th17 cells in human PBMCs by blocking gp130 and its subsequent STAT3 signaling cascade, and it was proposed as a gp130-specific inhibitor for treatment of RA (70).